Eventide Asset Management LLC Takes Position in Metsera Inc. $MTSR

Key Points

• Eventide Asset Management LLC has invested approximately $6.81 million in Metsera Inc. by acquiring 250,000 shares during the first quarter.
• Despite a reported loss of ($0.66) earnings per share for the last quarter, several analysts have given the stock a consensus rating of "Buy" with a price target of around $59.00.
• Metsera, Inc. develops next-generation hormonal treatments for obesity and has recently received positive ratings upgrades from multiple research firms.

Eventide Asset Management LLC bought a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 250,000 shares of the company's stock, valued at approximately $6,805,000. Eventide Asset Management LLC owned 0.24% of Metsera as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Alphabet Inc. bought a new stake in shares of Metsera in the first quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in Metsera in the 1st quarter valued at approximately $78,748,000. Invesco Ltd. bought a new stake in Metsera during the 1st quarter valued at $271,000. Jennison Associates LLC purchased a new stake in shares of Metsera during the first quarter worth $9,679,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Metsera in the first quarter worth $3,410,000.

Analyst Ratings Changes

Several brokerages have recently weighed in on MTSR. Leerink Partners began coverage on Metsera in a research report on Tuesday. They issued an "outperform" rating and a $77.00 price target for the company. Bank of America lifted their target price on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Guggenheim upped their price target on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company initiated coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Metsera presently has an average rating of "Buy" and a consensus price target of $63.50.

Metsera Stock Up 4.6%

Shares of MTSR stock traded up $1.62 during trading on Tuesday, hitting $36.72. The company had a trading volume of 1,836,148 shares, compared to its average volume of 1,032,531. The stock's 50-day moving average is $34.86 and its two-hundred day moving average is $28.65. Metsera Inc. has a 52 week low of $12.30 and a 52 week high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.